Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Non-alcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cencicriviroc, Others; By Disease Cause; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Outlook

The global Non-alcoholic Steatohepatitis (NASH) Treatment market is expected to grow at a CAGR of 43.7% during the period 2022-2027. North America, South America, Europe and Middle East are likely to be key markets.

 

Global Market Likely to be Driven by Rising Cases of NAFLD and NASH

Non-alcoholic steatohepatitis (NASH) is an aggressive form of non-alcoholic fatty liver disease (NAFLD). It is indicated by excessive accumulation of fat in the liver, inflammation, cell injury and fibrosis. Non-alcoholic fatty liver disease (NAFLD) is a significant cause of liver disease across the world. The global prevalence of NAFLD is estimated to be over 25% with maximum prevalence in the Middle East and South America, and lowermost in Africa.

 

Clinicians recommend weight loss to treat non-alcoholic fatty liver disease (NAFLD), either non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH). Weight loss could decrease fat, inflammation, and fibrosis—or scarring—in the liver. Losing weight and making healthy food choices could help improve NAFL or non-alcoholic steatohepatitis (NASH). While no medicines have been approved to treat NAFL or non-alcoholic steatohepatitis (NASH), researchers are engaged in studying medicines that may improve these conditions. If non-alcoholic steatohepatitis (NASH) leads to cirrhosis, doctors can treat several complications associated with cirrhosis with drugs, minor procedures, and surgery. Individuals with liver failure or liver cancer may require a liver transplant.

 

Therapies Under Development Expected to Stimulate Market Growth

It is estimated that non-alcoholic steatohepatitis (NASH) will leave behind hepatitis C virus infection as the leading cause of liver transplantation in USA in the following decade, thus, there is greater urgency to develop appropriate therapeutic solutions, particularly considering that diet and life-style modifications are at times difficult to maintain and by themselves have not been able to slow the spread of the disease. With time, the understanding of the pathogenesis and progression of non-alcoholic steatohepatitis (NASH) has developed and many promising new therapies to target and possibly reverse fibrosis are under evaluation, offering an optimistic and positive view of the future.  For example, in 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Pfizer’s under trial combination therapy intended to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis. Such developments are expected to boost the global non-alcoholic steatohepatitis (NASH) treatment market. Fast Track is a process devised to help the development and advance the review of novel vaccines and medicines meant to prevent or treat serious conditions and address unfulfilled medical needs.

 

Diacylglycerol O-acyltransferase 2 (DGAT2) and acetyl-CoA carboxylase (ACC) are two important enzymes that regulate lipid metabolism. Inhibitors of ACC and DGAT2 have exhibited the capability to decrease liver fat in patients with non-alcoholic fatty liver disease (NAFLD). Pfizer trusts that ervogastat/clesacostat, its under trial DGAT2i/ACCi combination therapy, has the capability to deliver direct improvements in inflammation and fibrosis.

 

Market Segmentation

By drug type, the global non-alcoholic steatohepatitis (NASH) treatment market is segmented into:

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib and Cencicriviroc
  • Others

 

By disease cause, the market is divided into:

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 diabetes
  • Obesity
  • Others

 

By end use, the market is classified into:

  • Hospitals
  • Clinics
  • Homecare Settings

 

By region, the market is segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global non-alcoholic steatohepatitis (NASH) treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

 

  • Zydus Cadila
  • Novartis AG
  • Pfizer Inc.
  • Madrigal Pharmaceuticals
  • Intercept Pharmaceuticals, Inc.
  • Genfit SA
  • Others

 

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Type
  • Disease Cause
  • End Use
  • Region
Breakup by Drug Type
  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib and Cencicriviroc
  • Others
Breakup by Disease Cause
  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 diabetes
  • Obesity
  • Others
Breakup by End Use
  • Hospitals
  • Clinics
  • Homecare Settings
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Zydus Cadila
  • Novartis AG
  • Pfizer Inc. 
  • Madrigal Pharmaceuticals
  • Intercept Pharmaceuticals, Inc.
  • Genfit SA
  • Others

 

*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface 
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions   
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Industry Opportunities and Challenges  
8    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market (2017-2021) 
    8.3    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast (2022-2027)
    8.4    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market by Drug Type
        8.4.1    Vitamin E and Pioglitazone
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Ocaliva
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Elafibranor
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Selonsertib and Cencicriviroc
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
        8.4.5    Others
    8.5    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market by Disease Cause
        8.5.1    Hypertension
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Heart Disease
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    High Blood Lipid
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Type 2 diabetes
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Obesity
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2017-2021)
            8.5.5.3    Forecast Trend (2022-2027)
        8.5.6    Others
    8.6    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market by End Use
        8.6.1    Hospitals
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Clinics
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Homecare Settings
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2017-2021)
            8.6.3.3    Forecast Trend (2022-2027)
    8.7    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Zydus Cadila
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Novartis AG
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Pfizer Inc. 
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Madrigal Pharmaceuticals
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Intercept Pharmaceuticals, Inc.
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Genfit SA
            11.2.6.1    Company Overview
            11.2.6.2    Product Portfolio
            11.2.6.3    Demographic Reach and Achievements
            11.2.6.4    Certifications
        11.2.7    Others
12    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market: Key Industry Highlights, 2017 and 2027
2.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Drug Type (USD Million), 2017-2021
3.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Drug Type (USD Million), 2022-2027
4.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Disease Cause (USD Million), 2017-2021
5.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Disease Cause (USD Million), 2022-2027
6.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by End Use (USD Million), 2017-2021
7.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by End Use (USD Million), 2022-2027
8.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Region (USD Million), 2017-2021
9.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Region (USD Million), 2022-2027
10.    North America Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
11.    North America Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Europe Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Europe Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Asia Pacific Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Asia Pacific Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Latin America Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Latin America Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Middle East and Africa Non-alcoholic Steatohepatitis (NASH) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
19.    Middle East and Africa Non-alcoholic Steatohepatitis (NASH) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
20.    Global Non-alcoholic Steatohepatitis (NASH) Treatment Market Structure.

Key Questions Answered in the Report

The market is estimated to grow at a CAGR of 43.7% between 2022 and 2027.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Non-alcoholic steatohepatitis, if not provided with proper care, might lead to a permanent liver damage. NASH treatment aims at nourishing liver to prevent it from getting deteriorated.

Hepatomegaly is a symptom of non-alcoholic steatohepatitis which causes enlargement of liver.

Green leafy vegetables and fibre rich fruits such as strawberries, avocado, and raspberries, among others, should be consumed during non-alcoholic steatohepatitis.

The major drivers of the market include the increasing prevalence of advanced liver diseases, growing cases of obesity, and rising geriatric population.

The rising healthcare expenditure across the emerging economies and increasing penetration of artificial intelligence in MRI and ultrasound procedures are the key trends in the market.

Vitamin E and pioglitazone, ocaliva, elafibranor, and selonsertib and cencicriviroc, among others are the different segments based on drug type in the market.

Hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity, among others is the segmentation of market based on disease cause.

Hospitals, clinics, and homecare settings are the different end-uses included in the market report.

The major players in the industry are Zydus Cadila, Novartis AG, Pfizer Inc., Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Inc., and Genfit SA, among others.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER